Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$131.68 -3.32 (-2.46%)
(As of 11/20/2024 ET)

Illumina - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
8
Buy
15

Based on 24 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 1 has given a sell rating, 8 have given a hold rating, 13 have given a buy rating, and 2 have given a strong buy rating for ILMN.

Consensus Price Target

$164.00
24.54% Upside
According to the 24 analysts' twelve-month price targets for Illumina, the average price target is $164.00. The highest price target for ILMN is $254.00, while the lowest price target for ILMN is $100.00. The average price target represents a forecasted upside of 24.54% from the current price of $131.68.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
7 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$164.00$155.50$151.10$194.56
Forecasted Upside24.54% Upside7.94% Upside15.00% Upside99.01% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside24.54% Upside26,931.55% Upside9.81% Upside
News Sentiment Rating
Positive News

See Recent ILMN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/12/2024Stephens
4 of 5 stars
 Boost TargetOverweight ➝ Overweight$170.00 ➝ $184.00+21.45%
11/12/2024Morgan Stanley
3 of 5 stars
 Reiterated RatingEqual Weight$156.00+2.97%
11/11/2024Piper Sandler
2 of 5 stars
 Lower TargetOverweight ➝ Overweight$195.00 ➝ $185.00+22.44%
11/6/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$124.00 ➝ $139.00-10.30%
11/5/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brennan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$166.00 ➝ $177.00+15.02%
11/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$133.00 ➝ $145.00-4.89%
11/5/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$252.00 ➝ $254.00+68.04%
11/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$125.00 ➝ $140.00-7.76%
11/5/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$155.00 ➝ $190.00+25.05%
11/5/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$135.00 ➝ $145.00-3.65%
11/5/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$130.00 ➝ $145.00-5.53%
10/17/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy$180.00+25.42%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$160.00 ➝ $200.00+38.91%
10/17/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$180.00+25.10%
8/28/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$150.00+14.59%
8/16/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/16/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$120.00 ➝ $154.00+19.57%
8/15/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Outperform ➝ Sector Outperform$176.00 ➝ $164.00+27.33%
6/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$195.00 ➝ $175.00+59.35%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$115.00+10.28%
3/20/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingPositive ➝ Mixed
12/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$155.00+22.37%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$175.00+48.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$140.00 ➝ $100.00-14.99%
10/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+49.91%
8/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$225.00 ➝ $200.00+8.41%
1/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$350.00 ➝ $296.00+42.78%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:55 AM ET.


ILMN Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $164.00, with a high forecast of $254.00 and a low forecast of $100.00.

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There is currently 1 sell rating, 8 hold ratings, 13 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ILMN shares.

According to analysts, Illumina's stock has a predicted upside of 24.54% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 3 upgrades by analysts.

Analysts like Illumina less than other "medical" companies. The consensus rating score for Illumina is 2.67 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ILMN compares to other companies.


This page (NASDAQ:ILMN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners